(Q41241253)

28 September 2017

A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents (English)

1 reference

28 September 2017

phase I clinical trial

0 references

author name string

Thomas M Braun

series ordinal

1

1 reference

28 September 2017

Shufang Wang

series ordinal

2

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

28 September 2017

1 reference

28 September 2017

66

1 reference

28 September 2017

3

1 reference

28 September 2017

805-812

1 reference

maintained by WikiProject

28 September 2017

WikiProject Mathematics

0 references

cites work

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Designs for single- or multiple-agent phase I trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Design and analysis of phase I clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Sequential continual reassessment method for two-dimensional dose finding

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Dose‐Finding with Two Agents in Phase I Oncology Trials

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Continual reassessment method for ordered groups

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Continual reassessment methods in phase I trials of the combination of two drugs in oncology.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Continual reassessment method: a likelihood approach.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2889231

Two-dimensional dose finding in discrete dose space

19 August 2018

1 reference

12 December 2020

Simultaneously optimizing dose and schedule of a new cytotoxic agent

1 reference

12 December 2020

A Comparison of Two Approaches to the Construction of Models for Quantal Responses to Mixtures of Drugs

1 reference

12 December 2020

An evaluation of phase I cancer clinical trial designs

1 reference

12 December 2020

10.1111/J.1541-0420.2009.01363.X

Identifiers

DOI

1 reference

28 September 2017

1 reference

28 September 2017

PubMed publication ID

19995354

1 reference